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Abstract 
Dimeric calpains constitute a promising therapeutic target for many diseases such as 
cardiovascular, neurodegenerative and ischaemic disease. The discovery of selective calpain 
inhibitors, however, has been extremely challenging. Previously, allosteric inhibitors of 
calpains, such as PD150606, which included a specific α-mercaptoacrylic acid sub-structure, 
were reported to bind to the penta-EF hand calcium binding domain, PEF(S) of calpain. 
Although these are selective to calpains over other cysteine proteases, their mode of action 
has remained elusive due to their ability to inhibit the active site domain with and without the 
presence of PEF(S), with similar potency. These findings have led to the question of whether 
the inhibitory response can be attributed to an allosteric mode of action or alternatively to 
inhibition at the active site.  In order to address this problem, we report a structure-based 
virtual screening protocol as a novel approach for the discovery of PEF(S) binders that 
populate a novel chemical space. We have identified compound 1, Vidupiprant, which is 
shown to bind to the PEF(S) domain by the TNS displacement method, and it exhibited 
specificity in its allosteric mode of inhibition. Compound 1 inhibited the full-length calpain-1 
complex with a higher potency (IC50 = 7.5 µM) than the selective, cell-permeable non-peptide 
calpain inhibitor, PD150606 (IC50 = 19.3 µM), where the latter also inhibited the active site 
domain in the absence of PEF(S) (IC50 = 17.8 µM). Hence the method presented here has 
identified known compounds with a novel allosteric mechanism for the inhibition of calpain-
1. We show for the first time that the inhibition of enzyme activity can be attributed to an 
allosteric mode of action, which may offer improved selectivity and a reduced side-effects 
profile. 
Allosteric inhibition, PEF(S), Calpain-1 inhibitors, Structure-based design, Docking 
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Introduction 
Calpains are proteins that belong to the family of calcium-dependent, non-lysosomal 
cysteine proteases expressed ubiquitously in mammals and other organisms.1 Although the 
physiological roles of calpains are still poorly understood, they have been shown to be 
involved in many processes such as cell motility, long-term potentiation in neurons and cell 
fusion in myoblasts.2 In particular, conventional dimeric calpains have been reported to be 
involved in the cell degeneration processes that characterize numerous disease conditions.3   
Calpain-1 (µ-calpain) and calpain-2 (m-calpain) are heterodimeric proteases composed of a 
large subunit with a molecular mass of ~80 kDa, sharing a small subunit of mass ~30 kDa. 
The small subunit consists of two domains, namely the penta-EF hand calcium binding 
PEF(S) and glycine rich (GR) domains, which are essential for stabilizing calpain-1 and 
calpain-2.4 High sequence similarity of 62% is exhibited by the large subunits of calpain-1 
and -2 in humans.4 And they consist of four different domains, an N-terminal anchor helix, 
the active site domain (CysPc), a domain that resembles the C2 membrane binding domains 
of phosphokinases, known as the C2L domain, and a second penta-EF hand calcium binding 
domain known as PEF(L). The PEF(L) domain is the determinant of the calcium 
concentration that is required for protease activation, which differentiates between the two 
isoforms: calpain-1 requires micromolar concentrations of Ca2+, whereas calpain-2 requires 
millimolar concentrations for activation.5  
Calpain-1 is a target dysregulated in many diseases such as neurodegenerative disorders, 
cardiovascular diseases, ischaemic disorders, arterial sclerosis, leishmaniasis and cancer.6,7 In 
most cases of disease, calpain-1 activity is elevated (and hence its inhibition would be 
beneficial in treatment). However, it has been recently suggested that the up regulation of 
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calpain-1 appears to be beneficial in some cases, such as stage II Alzheimer’s disease, where 
its activation could be neuroprotective and beneficial in controlling cellular damage.8 
Until recently, it has been challenging to design selective calpain-1 inhibitors, and this is 
attributed to the fact that most compounds that target the active site inhibit a broad spectrum 
of cysteine proteases, thereby resulting in undesirable side effects.9 For example, it has been 
previously reported that calpain-1 inhibitors,9 which also inhibit the proteasome may induce 
apoptosis, whereas selective calpain-1 inhibitors do not. Hence, it may be beneficial to design 
selective calpain-1 inhibitors to avoid off-target related side effects. 
Classical allosteric inhibitors of calpain-1, which were originally reported to bind to 
PEF(S), exhibit a very specific type of chemistry - that is α-mercaptoacrylic acid-based, such 
as PD150606 and PD151746.10 These inhibitors are potent, cell permeable and selective 
inhibitors of calpain-1 and calpain-2 exhibiting selectivity towards calpain over other 
cysteine proteases, with a slight selectivity for calpain-1 over calpain-2.  It has been reported 
however that PD150606 could equally inhibit the active site domain of calpain-1 without the 
presence of PEF(S).11 This clearly suggests that its mode of action is rather unclear. The 
reported α-mercaptoacrylic acid based calpain inhibitors (Figure 1. A. PD150606 and B. 
PD151746) and their disulfide analogues (Figure 1. C. and D.) were synthesized by Adams et 
al, and shown to bind to PEF(S) from X-ray diffraction analysis (PDB IDs: 1NX3, 4WQ2 
and 4WQ3).5,12-14 Additional calpain-1 inhibitors that were reported to inhibit the whole 
calpain-1 complex, which consists of the PEF(S) and CysPc (active site domain of calpain-1), 
are also depicted in Figure 1, including their chemical structures. CHEMBL203568,15 shown 
in Figure 1. E., is a compound reported to inhibit the calpain-1 complex with an IC50 value of 
4.9 nM. While CHEMBL20488315, shown in Figure 1. F., is a compound reported to inhibit 
the calpain-1 complex with an IC50 value of 8 nM. However, CHEMBL203568 and 
CHEMBL204883 have not been confirmed as PEF(S) binders i.e. exhibit an allosteric mode 
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of inhibition. Their reported confidence score is 7 (in ChEMBL) indicating that these 
compounds might be binding to any of the subunits involved in the full-length calpain-1 
complex. Hence, the use of PEF(S) (calpain-1 small subunit) in structure-based virtual 
screening may be an appealing approach for the design of allosteric calpain-1 binders with 
completely different structural architecture from the classical allosteric binders and inhibitors. 
In addition, this approach is expected to answer the question of whether PEF(S) binding 
would confer inhibition, given that the shortlisting of candidates is based on the prediction of 
their binding to PEF(S). 
 
 
Figure 1. PD150606 A.  PD151746 B. bind to the PEF(S) of calpain, and show modest 
selectivity for calpain-1 over calpain-2. Adams et al, 2015, synthesized their disulphide 
analogues C. and D. respectively, which bind to PEF(S) and were reported5 with improved 
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potencies in comparison to their monomer compounds E. CHEMBL203568, a compound 
reported to inhibit the calpain-1 complex (Uniprot IDs: P04632 and P07384) with an IC50 
value of 4.9 nM and confidence score of 7 F.  CHEMBL204883, a compound reported to 
inhibit the calpain-1 complex (Uniprot IDs: P04632 and P07384) with an IC50 value of 8 nM 
and confidence score of 7 
 
In this work, we have used the PEF(S) (PDB ID: 4WQ2, calpain-1 small subunit) in a 
structure-based virtual screening protocol to ascertain whether novel chemical series bind to 
the allosteric pocket. To validate this approach, purchasable ligands of diverse and novel 
structural frameworks (very different from those that have been previously investigated) were 
evaluated in silico, using ligand/protein docking against PEF(S), and the compounds were 
subsequently tested in relevant assays. This pipeline for the structure-based virtual screening 
protocol is depicted in Figure 2. 
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Figure 2. The pipeline of the structure-based virtual screening protocol followed for 
shortlisting candidates of PEF(S) binders started with the collection of a pool of compounds 
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with diverse chemical structures (very different from those that have been previously 
investigated), then candidates were shortlisted based on docking into the crystal structure of 
PEF(S) (PDB: 4WQ2, calpain-1 small subunit). The top ranked candidates were assessed for 
their chemical novelty in comparison to the classical allosteric binders and inhibitors using an 
MDS plot. The subset of compounds was then investigated using relevant experimental 
assays. 
 
 As a general approach, we hypothesised that the functional effect of PEF(S) binders on the 
active site of calpain-1 may be predicted by carrying out Molecular Dynamics (MD) 
simulations16,17 on the full-length calpain-1 complex (PEF(S) and CysPc) in both the unbound 
and the ligand bound states to the PEF(S) domain. If the bound compound increases the 
average distance between the substrate and the interacting residues in the active site of 
calpain-1, then we further hypothesise that it would inhibit the activity of the enzyme. In 
contrast, if the compound decreases this distance, it would favour the interactions between 
the enzyme and the substrate, thus facilitating the enzyme reaction. A crystal structure of the 
full-length calpain-1 complex (PEF(S) and CysPc) is currently unavailable, and hence we 
approached the problem by using the pipeline shown in Figure 2. Accordingly, the 
compounds that are predicted to bind to PEF(S) are either expected to inhibit or activate 
calpain-1. 
To explore the small molecule chemical architecture that would most likely alter the 
geometry of the calpain-1 active site, to inhibit its substrate cleavage allosterically, 
compounds with diverse chemical structures were investigated computationally based on 
their predicted binding affinities towards PEF(S). The candidate PEF(S) binders, which were 
shortlisted by the structure-based virtual screening protocol depicted in Figure 2 were 
sulphonamides, N{3[3(2alkoxyethoxy)5(4methoxyphenyl)s, and 
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[1,2,4]triazolo[4,3b]pyridazin6yl]pyridines. Experimentally these compounds were also 
shown to bind to PEF(S) by displacing TNS (which binds to the allosteric site).10 In addition, 
three compounds were able to inhibit the full-length calpain-1 complex (which includes 
PEF(S) and CysPc) allosterically, but not the active site domain of calpain-1 in the absence of 
PEF(S). The inhibitory activity, via a proposed allosteric mechanism is a crucial finding 
given that they show specificity in their mode of action, which is not the case for the classical 
allosteric inhibitors such as PD150606. The new inhibitors possess different scaffolds from 
the classical allosteric inhibitors. These compounds serve as a novel starting point for the 
expansion of the compound series (including SAR) to improve their potency. In addition, this 
finding suggests that compounds can inhibit the enzyme activity via the PEF(S) domain. An 
important aspect of this study is that by designing allosteric inhibitors, which do not inhibit 
the active site domain (that is common to a wide variety of cysteine proteases) these may be 
effective in treating calpain-1 related diseases without the side effects associated with 
inhibitors, which do inhibit the active site domain as well.18 
Results and Discussion 
Structure-based virtual screening of purchasable ligands against PEF(S) 
36,503 commercial compounds consisting of diverse chemical structures (sulphonamide-, 
amide-, pyridine-, urea-, enamine-based compounds), were docked using Glide19 into the pre-
prepared (see methods for details) protein crystal structure of human PEF(S) (PDB20ID: 
4WQ2).5 From the docking scores, the distribution for actives versus inactives was obtained. 
The active molecules displayed a more favourable distribution of scores, which allowed 
differentiation of actives and inactives (see methods for details). 
Candidate PEF(S) binders from the purchasable database were shortlisted on the basis of a 
cut-off with the highest Mathews Correlation coefficient. The cut-off obtained was -6.35, 
according to which compounds with more negative binding score were predicted to bind. The 
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selected candidates were further screened against PAINs21 (with regard to the recent analysis 
of the use of this approach (Tropsha))22 using the FAFDrug3 ADME-Tox Filtering Tool.23 
Those compounds that didn’t exhibit any potential PAINs liability were considered for 
evaluation of calpain-1 activity. As a result, five sulphonamides 1-5, two substituted N{3
[3(2alkoxyethoxy)5(4methoxyphenyl)s 6-7, and three substituted [1,2,4]triazolo[4,3
b]pyridazin6yl]pyridines 8-10, which were the top ranked compounds according to the 
virtual screening criteria, were shortlisted as candidates for PEF(S) binding. 
 
MDS plot shows that shortlisted PEF(S) binders occupy a novel region in chemical space 
An MDS plot of the chemical space was generated consisting of the ChEMBL compounds 
inhibiting the full-length calpain-1 complex (PEF(S) and CysPc) with IC50 values ≤ 1 µM, 
and the Adams library (a library of α-mercaptoacrylic acid calpain inhibitors and their 
disulfide analogues),5 which were validated against the PEF(S) docking model (see methods 
for details) (Figure 3). In addition, the shortlisted candidates 1-10 from the structure-based 
design protocol were also included in the plot, which enabled the assessment of the novelty of 
chemical space coverage of the shortlisted PEF(S) binders, in comparison to the classical 
calpain-1 inhibitors and PEF(S) binders. Figure 3, which is a two dimensional MDS plot 
based on Morgan fingerprints of radius 2 with 90% ellipse-like confidence regions, shows 
that the shortlisted compounds 1-10 exhibited new structures in comparison to the previously 
reported compounds by occupying a novel region in the chemical space of calpain-1 actives. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
 
 
Figure 3.  A two dimensional MDS plot based on Morgan fingerprints of radius 2, with 90% 
ellipse-like confidence regions for 32 ChEMBL compounds, 33 compounds synthesized by 
Adams et al,5 and the 10 shortlisted candidates from the structure-based design protocol. 
These were shortlisted from a purchasable database based on their high predicted binding 
affinity towards the PEF(S) domain of calpain via docking with Glide. The compounds 
identified belong to a new chemical space in comparison to the previously reported 
compounds that bind to the PEF(S) (Adams library) and the compounds which inhibit the 
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full-length calpain-1 complex. Compounds 1, 9, and 10 were then validated as novel 
allosteric inhibitors of calpain-1. 
 
FRET based Inhibition Assay  
A fluorogenic assay of the full-length calpain-1 complex (which includes PEF(S) and 
CysPc) was used to determine the activity of compounds 1-10. Amongst the identified 
compounds, 1, 9, and 10 inhibited the full-length calpain-1 complex with IC50 values of 7.5 
(±1.1), 20.5 (±1.9), and 29.7 (±5.2) µM, respectively (Table 1). The same experimental 
protocol was performed to measure the activity of compounds against the active site domain 
of calpain-1, without the presence of PEF(S), to investigate a possible allosteric mode of 
action.  None of the compounds showed any inhibition in the absence of PEF(S), except for 
compound 1, which weakly inhibited the active site domain with an IC50 value >100 µM. In 
contrast, compound 3 exhibited higher inhibitory activity against the active site domain of 
calpain-1 with an IC50 value of 41.1 (±15.4) µM as compared to the full-length calpain-1 
complex, which showed an activity of >100 µM, suggesting that in the presence of PEF(S) it 
preferentially binds to PEF(S). This could explain the reduction in its inhibitory activity since 
it is most likely unable to alter the geometry of the active site while it binds allosterically. 
The IC50 values were also measured for the classical α-mercaptoacrylic acid based calpain 
inhibitor, PD150606, and these were 19.3 (±1.6) µM with the full-length calpain-1 complex, 
and 17.8 (±2.4) µM with the active site domain without the presence of PEF(S). Hence, in 
contrast to compounds 1, 3, 9, and 10, PD150606 exhibited an unspecific mode of action by 
equally inhibiting via both binding sites (active and allosteric sites). It is worth stating here 
that compound 1 is an asthma drug, Vidupiprant or AMG 853,24, which exhibited higher 
potency than PD150606 in inhibiting the enzyme activity. The dose response curve of 
compound 1 (IC50 = 7.5±1.1 µM) is displayed in Figure S1. Interestingly, identifying 
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Vidupiprant as an allosteric inhibitor of calpain-1 is in agreement with previous reports 
showing a direct link between calpain inhibition and anti-inflammatory properties, where it 
was shown that non-steroidal anti-inflammatory drugs (NSAIDs) inhibit calpain, and that 
calpain inhibition reduces allergic inflammation.25,26 Potentially, this finding could highlight 
the importance of considering calpain inhibitors for the development of new anti-asthmatic 
therapies.   
 
 
Compound Common Scaffold Substituents 
IC50 full-
length 
calpain-1 
complex 
(µM) 
IC50 
active site 
domain 
calpain-1 
(µM) 
1 
 
R1 and R4 = H 
R2=  
 
R3 = Cl 
R5 =  
R6 = 
 
X = C 
7.5 ±1.1 >100 
2 
R1, R3, R4, and R6 
=H 
R2 = CF3 
NR NR 
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R5 =  
X = C 
3 
R1 =  
R2 = CO2H 
R3, R4, and R6 = H 
R5 = F 
X = N 
> 100 41.1 
±15.4 
4 
R1, R3, R5 and R6 
=H 
R2 =  
R4 = CF3 
X = C 
 
NR NR 
5 
R1, R3, R5 and R6 
=H 
 
R2 =  
R4 = CF3 
X = C 
 
NR NR 
6 
 
R1 = CF3 
R2 = H 
 
R3 =  
NR NR 
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7 
R1 = H 
R2 = OCH3 
R3 =  
NR NR 
8 
 
 
NR NR 
9 
 
20.5 ±1.9 NR 
10 
 
29.7±5.2 NR 
PD150606 
 
19.3 ±1.6 17.8±2.4 
 
Table 1. IC50 values for compounds 1-10, and PD150606 determined by the FRET based 
inhibition assay, with the full-length calpain-1 complex and the active site domain of calpain-
1, reported as mean +/- standard deviations from three independent experiments (NR = no 
response) 
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The allosteric inhibitory activity exhibited by compounds 1, 9, and 10 validates the design 
approach, which shortlisted PEF(S) binders. The three active compounds include scaffolds, 
which are distinct from the classical allosteric inhibitors. The IC50 values obtained could be 
improved by efficient choice of substituents using standard medicinal chemistry approaches. 
In particular compound 1, which is a sulphonamide, exhibited specificity in its allosteric 
inhibition of calpain-1, and was more potent (7.5 µM) than PD150606 (19.3 µM), which 
additionally inhibits the active site domain, in the absence of PEF(S), with a similar IC50 
value. 
TNS Displacement Assay 
TNS, which is a sensitive fluorophore that binds to PEF(S) was used to probe protein 
dynamics and conformational change. It fluoresces in the bound state i.e. in a hydrophobic 
environment, whereas when another compound displaces it, its fluorescence gets quenched. 
This fluorophore was used previously to assess the binding of PD150606 to PEF(S), a 
compound which has been already shown to bind to PEF(S) by X-ray crystallography (PDB 
ID: 1NX3).10,12 In this work, PD150606 (as a control), compound 1, the most potent allosteric 
inhibitor, compound 3, a weak allosteric inhibitor, and compounds 2, 4 and 5, which did not 
exhibit any inhibitory activity, have been tested for PEF(S) binding by the TNS displacement 
method. The results for compounds 6-10 were unreliable as it became apparent that they 
fluoresced under the assay conditions, therefore for this reason these results were omitted. As 
shown in Figure 4, all tested compounds, except for compound 5, quenched the fluorescence 
of TNS, exhibiting a similar trend in their quenching effect to that of the known PEF(S) 
binder, PD150606, hence confirming their binding to PEF(S). Therefore, it appears that 
compounds 2-4 do indeed bind to PEF(S) in a similar fashion to compound 1, but they either 
weakly inhibited or failed to allosterically alter the geometry of the active site.  
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Figure 4. PD150606, which was shown by X-ray crystallography to bind to PEF(S) (PDB 
ID: 1NX3), compound 1 (the most potent allosteric inhibitor), 3, which was the least potent 
among the identified allosteric inhibitors, 2 and 4, which did not exhibit any inhibitory 
activity, all quenched the fluorescence of TNS. All compounds showed a similar effect to that 
of PD150606 confirming their binding to PEF(S), except for compound 5, which neither 
exhibited any inhibitory activity nor displaced TNS.  
 
Analysis of molecular docking studies of representative calpain-1 inhibitors 1 and 10, and 
compounds 2-5 
Docking studies predicted molecular interactions of the sulphonamide 1 and the 
[1,2,4]triazolo[4,3-b]pyridazin-6-yl]pyridine 10 with the PEF(S) protein crystal structure 
(PDB ID: 4WQ2). Figure 5.A. shows the 2-chloro-4-cyclopropylsulfonamido phenyl ring of 
compound 1 is π-stacked with His131, and the carbonyl of its carboxylic acid moiety H-bonds 
with same residue, the carbonyl of its amide moiety H-bonds with Trp168, and the phenyl ring 
attached to the tert-butylcarbamoyl moiety is π-stacked with the same residue. Figure 5.B. 
shows a π-stacking interaction between the pyridine ring of compound 10 and Trp168, and H-
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bonding of the nitrogen in that ring with the same residue. The hydrophobic interactions 
predicted for compounds 1 and 10 with Trp168 are also seen in the co-crystallised 
ligand/protein crystal structure (PDB ID: 4WQ3).5 In addition, a more favourable binding 
affinity towards PEF(S) was predicted for compound 1 (IC50 = 7.5 ±1.1 µM) as compared to 
compound 10, (IC50 = 29.7 ±5.2 µM), which could be the reason for the higher inhibitory 
activity exhibited by compound 1. In order to further explore the activities of compounds 1-
10, MD simulations on the full-length calpain-1 complex, which includes the PEF(S) domain 
would be beneficial once the crystal structure is available. The inhibitory activity of each 
compound is predicted to correlate with the average distance between the substrate and the 
interacting residues in the active site of calpain-1. 
 
 
Figure 5. Docking studies predicted molecular interactions of compounds 1 and 10 with 
the human PEF(S) of calpain-1 small subunit (regulatory subunit) protein crystal structure 
(PDB ID: 4WQ2). A. The 2-chloro-4-cyclopropylsulfonamido phenyl ring of compound 1 
shows π-stacking with His131 and the carbonyl of its carboxylic acid moiety H-bonds with the 
same residue. The carbonyl of its amide moiety H-bonds with Trp168 and the phenyl ring 
attached to the tert-butylcarbamoyl moiety is π-stacked with the same residue
 
B. The pyridine 
ring of compound 10 is π-stacked with Trp168 and the nitrogen of that ring H-bonds with 
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same residue. The hydrophobic interactions of 1 and 10 with Trp168 are also seen in the co-
crystallised ligand/protein crystal structure (PDB ID: 4WQ3).5  
 
Docking studies predicted molecular interactions of the sulphonamides 2-5 with the PEF(S) 
protein crystal structure (PDB ID: 4WQ2), which suggest that the hydrophobic interactions 
with Trp168 are essential for PEF(S) binding. Figure 6.A. shows that the phenyl ring of 
compound 2, which is attached to the sulfonyl moiety is π-stacked with Trp168, and the same 
residue H-bonds with the carbonyl of the amide group, the hydroxyl of its cyclohexyl ring H-
bonds with Gln100, and its sulfonyl group H-bonds with His131. Figure 6.B. displays the 
predicted molecular interactions between compound 3 and the PEF(S) crystal structure, and 
these are H-bonding between its carboxyl moiety and the Lys172 and Trp168 residues, H-
bonding between its sulfonyl group and His131, and π-stacking with the Trp168 via its pyridine 
ring. Figure 6.C. demonstrates the predicted molecular interactions for compound 4, the 
amino group of its amide moiety H-bonds with the Glu97 and Trp168 residues, the phenyl ring 
of its benzamide group π-stacks with Trp168, and the carbonyl of its amide moiety H-bonds 
with Lys172. Figure 6.D. shows the H-bonding interactions predicted for the carbonyl of the 
oxopyrrolidin-1-yl moiety in compound 5 and the Lys172 and Trp168 residues, and H-bonding 
interactions for its sulfonyl moiety with His131, and π-stacking of the same residue with the 
phenyl ring of its trifluoromethylbenzene moiety. Hence, the hydrophobic interactions 
predicted for compounds 1-4 with Trp168 are also seen in the co-crystallised ligand/protein 
crystal structure (PDB ID: 4WQ3).5 However, compound 5 was predicted to exhibit 
hydrophilic interactions with Trp168, which could explain why it didn’t displace TNS, 
suggesting that the hydrophobic interactions with this residue are essential for PEF(S) 
binding. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
 
 
Figure 6.  Docking studies predicted molecular interactions of the sulphonamides 2-5 with 
the PEF(S) protein crystal structure (PDB ID: 4WQ2), which suggest that hydrophobic 
interactions with Trp168 are essential for PEF(S) binding A.  The phenyl ring of compound 2, 
which is attached to the sulfonyl moiety is π-stacked with Trp168, and the same residue H-
bonds with the carbonyl of its amide group, the hydroxyl of its cyclohexyl ring H-bonds with 
Gln100, and its sulfonyl group H-bonds with His131 B. H-bonding interactions are predicted to 
occur between the carboxyl moiety of compound 3 and the Lys172 and Trp168 residues, H-
bonding between its sulfonyl group and His131, and π-stacking with the Trp168 via its pyridine 
ring C. The amino group of the amide moiety for compound 4 H-bonds with Glu97 and 
Trp168, and the phenyl ring of its benzamide group π-stacks with Trp168, and the carbonyl of 
its amide moiety H-bonds with Lys172 D. H-bonding interactions are predicted to occur 
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between the carbonyl of the oxopyrrolidin-1-yl moiety for compound 5 and the Lys172 and 
Trp168 residues, H-bonding between its sulfonyl moiety and His131, and π-stacking of the 
same residue with the phenyl ring of its trifluoromethylbenzene moiety.   
 
Computational assessment of CNS permeability for representative calpain-1 inhibitors 1 and 
10 
Given that calpain-1 may serve as a therapeutic target for neurodegenerative disorders, the 
computational assessment of the CNS permeability for compounds 1 and 10 was performed 
with FAFDrug323 to see whether these compounds could be considered as good starting 
points to target these diseases. Their physicochemical properties were calculated using 
FAFDrug3. Following this, CNS diagrams were obtained and are presented in Figure S2. A 
and B. Compound 1 did not pass the CNS filter, which takes into consideration the 
assessment of its ability to pass the blood brain barrier. Hence, it is predicted not to exhibit 
the desired permeability,27 since the values of all the descriptors for compound 1 (logP, HBD, 
HBA, MW, tPSA (blue line)) fall outside the CNS filter area (light blue). As for compound 
10, it is predicted to exhibit medium permeability since all the descriptors, except for the 
HBA, have passed the CNS filter. Hence, compound 10 might serve as a good starting point 
for analogue development to target neurodegenerative diseases. 
 
 
Conclusions 
In this work, we have successfully validated our structure-based design method, which has 
led to the discovery of chemically novel allosteric inhibitors of calpain-1, and we have shown 
for the first time an allosteric mode of action. Compounds 1, 9, and 10 inhibited the full 
length calpain-1 complex (which includes PEF(S) and CysPc) with IC50 values of 7.5 (±1.1), 
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20.5 (±1.9), and 29.7 (±5.2) µM respectively. Compounds 9 and 10 did not inhibit the active 
site domain of calpain-1 in the absence of PEF(S), and compound 1 inhibited the active site 
domain weakly with an IC50 value >100 µM. In contrast, compound 3 exhibited higher 
inhibitory activity against the active site domain of calpain-1 with an IC50 value of 41.1 
(±15.4) µM as compared to the full-length calpain-1 complex, which was >100 µM 
suggesting that it preferentially binds to PEF(S). In addition, the IC50 values were measured 
for PD150606, giving 19.3 (±1.6) µM with the full-length calpain-1 complex and 17.8 (±2.4) 
µM with the active site domain (without the presence of PEF(S)). In comparison to the 
classical α-mercaptoacrylic acid based calpain inhibitor, PD150606, compounds 1, 9, and 10, 
exhibited specificity in their allosteric mode of action, since they didn’t inhibit the active site 
domain in the absence of PEF(S).  
Furthermore, PD150606, compound 1, the most potent allosteric inhibitor, compound 3, a 
weak allosteric inhibitor, and compounds 2 and 4, (which did not exhibit any inhibitory 
activity) have been tested for PEF(S) binding by the TNS displacement method. All 
compounds (1-4) quenched the fluorescence of TNS, exhibiting a similar trend in their 
quenching effect to that of the known P F(S) binder, PD150606.  
IC50 values obtained for compounds 1, 9, and 10 may be good starting points for 
optimisation, having novel scaffolds. Allosteric inhibitors discovered by this approach could 
exhibit more selectivity towards calpain-1 since they are unlikely to inhibit the active site 
domain, which is similar for a wide variety of cysteine proteases. This could translate to more 
effective treatments with less side effects for calpain-1 related diseases.18 
 
Materials and Methods 
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Extracting purchasable compounds for structure-based virtual screening against PEF(S), the 
calpain small subunit 1 (regulatory subunit) 
Purchasable compounds (36,503) with diverse chemistry (sulphonamide-, amide-, pyridine-, 
urea-, enamine-based compounds), were downloaded from the Aldrich market select 
database-2016.28 
 
Ligand Preparation   
The entire set of extracted ligands were prepared for docking with LigPrep 2.529 using the 
default settings and the Epik option, which introduces energy penalties associated with 
ionization and tautomerization.30 
Receptor Preparation of PEF(S)  
Docking with Glide19 was performed against human PEF(S), calpain-1 small subunit 
(regulatory subunit) of the protein crystal structure (PDB20 ID: 4WQ2)5 bound to (Z)-3-(6-
bromondol-3-yl)-2-mercaptoacrylic acid. The structure was prepared using the protein 
preparation wizard of Maestro 9.3,29 following the default protocol, which accounts for 
energy refinement, hydrogen addition, pKa assignment, and side-chain rotational isomer 
refinement. Resolved water molecules were discarded and the structure was centred using the 
co-crystallized ligand as the centre of the receptor grid generated for the protein structure. 
The co-crystal structure of the human calpain PEF(S) protein crystal structure (PDB ID: 
4WQ2) bound to (Z)-3-(6-bromondol-3-yl)-2-mercaptoacrylic acid was selected as the target 
structure.   
Cut-off generation for compound selection from docking model 
In an attempt to validate the docking model, a set of known active and inactive compounds 
were docked against the PEF(S) protein crystal structure to ensure that it enriched actives. 32 
ChEMBL31 compounds with IC50 values ≤ 1 µM (protein complex of the calpain-1, catalytic 
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and small regulatory subunits: P07384, P04632 with confidence scores of 6 or 7) were 
docked against the PEF(S) model. In addition, 20 inactive compounds from PubChem32 of the 
PEF(S) calpain-1 small regulatory subunit (Uniprot ID: P04632) were docked.  
 A good separation was obtained for the medians of docking score distribution for actives 
versus inactives for the docking model indicating that the actives are enriched. Figure S3. 
shows the separation of the medians for the PEF(S) docking model, -7.48 (actives) vs. -4.60 
(inactives). In addition, the indole and the phenyl α-mercaptoacrylic acid-based inhibitors and 
their disulfide analogues, which were synthesized by Adams et al,5 and shown by X-ray 
crystallography to bind to PEF(S), were docked against the PEF(S) docking model. The 
median of the docking score distribution obtained is -7.25 in comparison to the median of 
inactives, which is -4.60 (Figure S4., supporting information), which further validates that the 
model enriches these set of actives. Mann-Whitney test, which included statistical analysis on 
the active and inactive docking score distributions, was performed with R33 using the script 
provided by Kalash et al. 34 The differences in the medians was significant with p values less 
than 0.05. 
 
The Matthews correlation coefficient (MCC), which takes into account true and false 
positives and negatives, was computed using a Python script34 for all the docking scores of 
the ChEMBL actives and PubChem inactives for the model. A search was performed for a 
docking score threshold that gave the highest MCC for the docking model in order to shortlist 
purchasable candidates of PEF(S) binders, which displayed docking scores that are lower 
than that with the highest MCC for the PEF(S) docking model (which was -6.35). 
 
Docking 
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The purchasable compounds, prepared according to the protocol described, were docked 
against the PEF(S) protein crystal structure (PDB ID: 4WQ2). The Glide docking parameters 
included extra precision (XP) and the flexible ligand sampling option. These were deduced 
from docking experiments using known actives and inactives against the protein model.  The 
highest ranked compounds with respect to predicted affinity towards PEF(S) were selected 
for binding assessment and calpain-1 activity evaluation i.e. those which displayed docking 
scores that are lower than that with the highest MCC for the PEF(S) docking model, which 
was -6.35. The compounds that did not exhibit potential PAINs21,22 liabilities upon virtual 
screening with the FAFDrug3 ADME-Tox filtering tool, were selected for experimental 
validation.23 The shortlisted compounds exhibited diverse structures, with five sulphonamides 
1-5, two substituted N{3[3(2alkoxyethoxy)5(4methoxyphenyl)s 6-7, and three 
substituted [1,2,4]triazolo[4,3b]pyridazin6yl]pyridines 8-10.  
Multi-Dimensional Scaling (MDS) analysis of the shortlisted compounds 1-10 
This step of the analysis aimed to plot the chemical space of ChEMBL compounds which are 
active against the full-length calpain-1 complex, with IC50 values ≤ 1 µM (protein complex of 
calpain-1, catalytic and small regulatory subunits: P07384, P04632 and confidence scores of 
6 or 7), and the Adams library,5 which were validated against the PEF(S) docking model. In 
addition, the shortlisted candidates from the structure-based design protocol were included in 
the same plot. This analysis enables an assessment of the novelty of the chemical space 
coverage of the shortlisted compounds 1-10. For this purpose, the SMILES of all compounds 
involved were standardized using the ChemAxon Command-Line Standardizer, where the 
following options were selected: “Remove Fragment” (keep largest), “Neutralize”, 
“RemoveExplicitH”, “Clean2D”, “Mesomerize” and “Tautomerize”.35 
Subsequently, Morgan fingerprints (radius 2, 1024 bits) were generated for all the compounds 
using KNIME 2.11.3.36 The workflow generated Morgan fingerprints in the following 
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sequence: It (a) read chemical data from an SDF file, (b) generated RDKit molecules from a 
molecule string representation (SDF), (c) generated hashed bit-based fingerprints for an input 
RDKit Mol column (d) converted RDKit molecules into string based molecule 
representations (SDF or smiles) (e) excluded columns from the input table (f) renamed 
columns (g) and saved data table into a CSV file. 
A 2D-similarity matrix based on Euclidean distance was computed with R, using the 
generated Morgan fingerprints. Then, a metric multidimensional scaling of the similarity 
matrix was computed by embedding it into two dimensions (k=2). Subsequently, a 2D-plot 
was obtained, with the x-axis and the y-axis labelled, Dimension 1 and Dimension 2 
respectively. These are two relative and unit-less dimensions that recapitulate the pairwise 
similarity of all points observed in the distribution of Euclidean distances in a lower 
dimensional space. For each data set in the plot (corresponding to Adams library, ChEMBL 
compounds, and the shortlisted compounds), 90% confidence ellipses were computed using 
the ellipse package. Finally, based on the generated Morgan fingerprints, an MDS plot with 
90% ellipse-like confidence regions was obtained using the R ggplot2 package.37 
 
Expression and purification of PEF(S) 
The codon optimised gene encoding human PEF(S) was purchased from Epoch Biolabs 
(Texas, USA) in a pET21d vector. Human PEF(S) was produced in E. coli BL21-CodonPlus 
(DE3)-RP (Agilent Technologies), and purified using the same procedure previously 
described for PEF(S).5 
 
Evaluating calpain-1 activity of the shortlisted candidates of PEF(S) binders 1-10 
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This assay uses a fluorogenic peptide from the calpain-1 substrate α-spectrin, containing a 
FAM-DABCYL FRET pair (H2N-K(FAM)-EVYGMMK(DABCYL)-OH). Cleavage by 
calpain-1 occurs between the Tyr-Gly residues and results in enhanced fluorescence as the 
quenching effect is relieved. The assays using purified porcine calpain-1 (CalBiochem, 25 
nM) were performed in a buffer containing 1 µM calpain-1 substrate, 10 mM HEPES, 10 mM 
DTT, 0.5 mM EDTA, bovine serum albumin (0.1%) pH 6.8. The assay was carried out using 
a fluorescent plate reader (BMG Optistar) with a final assay volume of 100 µl at a 
temperature of 37°C, using an excitation band pass filter centred at 490 nm and emission 
detected at 520 nm. The compounds were added to the assay mixture before the reaction was 
initiated by the addition of CaCl2 (5 mM). None of the compounds had significant 
fluorescence at this wavelength. The compounds were dissolved in DMSO at 40 mM and 
diluted into assay buffer to give range of concentrations from 5 nM to 200 µM. In each assay 
run, the effect of DMSO alone over the concentration used was also measured. Although 
there was no effect of DMSO at lower concentrations, in some assay runs, DMSO at 0.005%-
0.5% produced some inhibitory effect. This DMSO effect (which was only relevant for 
compounds with poor inhibitory ability) was subtracted before constructing the inhibition 
curves.5 The IC50 values were obtained by fitting the data with non-linear regression with the 
SigmaPlot software,38 and the reported results are the mean +/- standard deviation of three 
independent experiments. 
TNS displacement for compounds 1-5  
10 µM PEF(S) in 20 mM Tris base, 1.1 mM CaCl2, 1 mM EDTA and pH 7.4 was incubated 
with 46.7 µM 2-p-toluidinylnaphthalene-6-sulfonate (TNS, 1mM stock in 40% ethanol) in a 
Greiner CELLSTAR 96 well black flat bottom plate for 5 minutes at 25 °C. 
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Compounds 1-10 were stored as 40 mM stock solutions in DMSO, then diluted from 500 
µM to 500 nM by serial dilution over 10 wells with an Integra Viaflow 96 multichannel 
pipette in triplicate. 
 
The plates were then incubated in a FLUOstar Omega plate reader at 25 °C for 5 minutes 
then were analysed using an excitation wavelength of 355 nm and an emission wavelength of 
450 nm with 10 flashes per well with orbital averaging. 
 
The baseline (just TNS) was subtracted from the fluorescence (B). B was then subtracted 
from the Bmax (with no inhibitor) to invert the data. The data was plotted in excel as bar 
diagrams for the mean +/- standard deviation of three independent experiments (n=3) in 
triplicate as shown in Figure 4. Whereas for compounds 6-10, their fluorescence interfered 
with TNS, (refer to Figure S5. for the blanks obtained for compounds 1-10) for this reason 
their results were omitted. 
Compounds and reagents Compound 1 was purchased from Tocris, and compounds 2-10 
were purchased from Ambinter, and used without further purification. PD150606 was 
purchased from Sigma Aldrich and used without further purification.  
Cloning of CysPC gene 
The pET28a-GB1-MAAKLVFF plasmid, a kind gift from Dr Cornelius Krasel of the Institut 
für Pharmakologie (Marburg, Germany), was used to create a Golden Gate acceptor plasmid 
by standard PCR, overlap extension PCR, endonuclease digestion and T4 DNA ligase 
reactions. When subjected to Golden Gate digestion/ligation with BsaI and T4 DNA ligase 
with an appropriate complimentary PCR product, the resulting plasmid has a section of DNA 
encoding RF under a constitutive promotor removed and the PCR product is incorporated in 
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such a fashion that the translation product contains the protein of interest with an N-terminal 
hexahistidine tag GB1 fusion tag that can be removed by the action of tobacco etch virus 
protease (TEV). 
Digestion/ligation proceeds as expected despite the presence of an additional BsaI site within 
the sequence encoding RFP. The CysPC domain of calpain-1 was inserted into this acceptor 
by PCR with the following primers: 
Fwd:  CGACTAGTGGTCTCCAGTCCATGGGTCGCCATGAGAA 
Rev: CGACTAGTGGTCTCCATCAGTCCGGGGTCAGGTTACA for ligation using the 
golden gate protocol into the pET28a-GB1-MAAKLVFF plasmid.39 
Plasmid Sequencing 
T7 Fwd 
TAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGGCAGCAGCCATCAT
CATCATCATCACACTTACAAATTAATCCTTAATGGTAAAACATTGAAAGGCGAAAC
AACTACTGAAGCTGTTGATGCTGCTACTGCAGAAAAAGTCTTCAAACAATACGCT
AACGACAACGGTGTTGACGGTGAATGGACTTACGACGATGCGACTAAGACCTTTA
CAGTTACTGAACATATGGAAAACCTGTATTTTCAGTCCGAGACCTTTACGGCTAGC
TCAGCCCTAGGTATTATGCTAGCTACTAGAGAAAGAGGAGAAAAACTAGTATGGTT
AGCAAAGGCGAGGAGCTGATTAAGGAGAATATGCACATGAAACTGTACATGGAAG
GCACCGTGAACAACCACCACTTCAAGTGCACCAGCGAGGGTGAAGGCAAACCGT
ATGAAGGCACCCAGACCATGCGTATCAAAGTGGTTGAGGGTGGCCCGCTGCCGTT
CGCGTTTGATATTCTGGCGACCAGCTTCATGTACGGTAGCCGTACCTTTATCAACCA
CACCCAGGGCATTCCGGATTTCTTTAAACAGAGCTTCCCGGAAGGTTTTACCTGGG
AGCGTGTGACCACCTACGAAGACGGTGGCGTTCTGACCGCGACCCAGGACACCA
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GCCTGCAAGATGGCTGCCTGATCTATAACGTGAAGATTCGTGGTGTTAACTTTCCG
AGCAACGGCCCGGTGATGCAGAAGAAAACCCTGGGTTGGGAGGCGAACACCGA
AATGCTGTATCCGGCGGATGGTGGCCTGGAGGGCCGTAGCGACATGGCGCTGAAG
CTGGTTGGTGGCGGTCACCTGATCTGCAACTTCAAAACCACC 
 
T7 Rev 
CGGGCTTTGTTAGCAGCCGGATCTCAGTGGTGGTGGTGGTGGTGCTCGAGTTATC
AGGAGACCGCTAGTTCAGTTTGTGACCCAGCTTGCTCGGCAGATCGCAATAACGC
GCAACCGCCACTTCGTGTTGCTCAACGTAGGTCTCTTTATCCGCTTCCTTAATACGC
TCCAGACGGTGATCAACATAGTACACACCCGGCATTTTCAGGTTCTTCGCCGGTTT
CTTGCTACGATAGGTGGTTTTGAAGTTGCAGATCAGGTGACCGCCACCAACCAGC
TTCAGCGCCATGTCGCTACGGCCCTCCAGGCCACCATCCGCCGGATACAGCATTTC
GGTGTTCGCCTCCCAACCCAGGGTTTTCTTCTGCATCACCGGGCCGTTGCTCGGA
AAGTTAACACCACGAATCTTCACGTTATAGATCAGGCAGCCATCTTGCAGGCTGGT
GTCCTGGGTCGCGGTCAGAACGCCACCGTCTTCGTAGGTGGTCACACGCTCCCAG
GTAAAACCTTCCGGGAAGCTCTGTTTAAAGAAATCCGGAATGCCCTGGGTGTGGT
TGATAAAGGTACGGCTACCGTACATGAAGCTGGTCGCCAGAATATCAAACGCGAA
CGGCAGCGGGCCACCCTCAACCACTTTGATACGCATGGTCTGGGTGCCTTCATACG
GTTTGCCTTCACCCTCGCTGGTGCACTTGAAGTGGTGGTTGTTCACGGTGCCTTCC
ATGTACAGTTTCATGTGCATATTCTCCTTAATCAGCTCCTCGCCTTTGCTAACCATAC 
 
Expression and purification of CysPC 
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BL21-CodonPlus (DE3) RP cells containing the human calpain-1 CysPC gene were grown at 
37 °C in kanamycin selective LB media until OD600 = 0.6 then induced with 1 mM IPTG. 
The protein was expressed overnight at 20 °C and cells harvested by centrifugation in a 
Sorvall RC6 Plus centrifuge (Thermo Fisher Scientific, Inc, MA, USA) using an SLA-3000 
rotor at 6080 RCF for 20 minutes at 4 °C. The cells were re-suspended in 20 mM HEPES, 
100 mM NaCl, 0.5 mM TCEP pH 7.6 (buffer A) and lysed by sonication for 5 mins (pulsed 5 
s on, 10 s off). The lysate was clarified by centrifugation at 4 °C for 40 minutes at 30310 RCF 
in a Sorvall RC6 Plus centrifuge. The supernatant was passed through a 0.2 µm syringe filter 
and applied to a Ni-NTA column. The bound protein was washed with 15 CV buffer A and 
eluted with 10 CV buffer A containing 250 mM imidazole, which was further dialyzed in 
buffer A overnight in a 10 kDa membrane containing 1 mL aliquot of TEV protease. The 
cleavage product was then passed back through a Ni-NTA column to remove the 6xHis-GB1 
solubility tag and TEV protease, with the flow through containing active CysPC as confirmed 
by SDS-PAGE, mass spectrometry and calpain-1 activity assay.  
 
Expression and purification of TEV protease 
BL21 (DE3) cells containing the TEV gene codon optimised for E. coli expression was 
obtained from Prof. Nigel Richards (Cardiff University).  
  
The cells containing the TEV protease gene were grown at 37 °C in ampicillin selective LB 
media until OD600 = 0.6 then induced with 1 mM IPTG. The protein was expressed overnight 
at 20 °C and cells harvested by centrifugation in a Sorvall RC6 Plus centrifuge (Thermo 
Fisher Scientific, Inc, MA, USA) using an SLA-3000 rotor at 6080 RCF for 20 minutes at 4 
°C. The cells were re-suspended in 20 mM HEPES, 100 mM NaCl, 0.5 mM TCEP pH 7.6 
(buffer A) and lysed by sonication for 5 mins (pulsed 5 s on, 10 s off). The lysate was 
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clarified by centrifugation at 4 °C for 40 minutes at 30310 RCF in a Sorvall RC6 Plus 
centrifuge. The supernatant was passed through a 0.2 µm syringe filter and applied to a Ni-
NTA column. The bound protein was washed with 15 CV buffer A and eluted with 10 CV 
buffer A containing 250 mM imidazole. The eluent was mixed with 20% v/v glycerol (20 mL 
final volume), and stored at -80 °C in 1 mL aliquots. 
Abbreviations 
 PEF(S): penta-EF hand calcium binding domain; TNS: p-toluidinylnaphthalene-6-
sulfonate; CysPc: calpain-like protease domain; kDa: kilo Dalton; SAR: structure activity 
relationship; NR: no response; CNS: central nervous system; HBD: hydrogen bond donor; 
HBA: hydrogen bond acceptor; tPSA: topological polar surface area; MW: molecular weight. 
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Highlights 
• The PEF(S) crystal structure was employed in virtual screening for the first time. 
• Compound 1, Vidupiprant was shown to bind to the PEF(S) domain.  
• Compound 1 inhibited calpain-1 with a higher potency than PD150606. 
• Compound 1 has shown specificity in its allosteric mode of inhibition. 
•  Novel allosteric mechanism for calpain-1 inhibition was identified. 
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